Cleared Traditional

THE EXPANDACELL EAR PACK (K940133) - FDA 510(k) Clearance

Class I Ear, Nose, Throat device.

K940133 · Denver Splint Co. · Ear, Nose, Throat device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
May 1994
Decision
140d
Days
Class 1
Risk

K940133 is an FDA 510(k) clearance for the THE EXPANDACELL EAR PACK. Classified as Applicator, Ent Drug (product code LRD), Class I - General Controls.

Submitted by Denver Splint Co. (Englewood, US). The FDA issued a Cleared decision on May 23, 1994 after a review of 140 days - within the typical 510(k) review window.

This device falls under the Ear, Nose, Throat FDA review panel, regulated under 21 CFR 874.5220 - the FDA ear, nose and throat device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Ear, Nose, Throat review framework, consistent with the majority of Class II 510(k) submissions.

View all Denver Splint Co. devices

Submission Details

510(k) Number K940133 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received January 03, 1994
Decision Date May 23, 1994
Days to Decision 140 days
Submission Type Traditional
Review Panel Ear, Nose, Throat (EN)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
51d slower than avg
Panel avg: 89d · This submission: 140d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code LRD Applicator, Ent Drug
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 874.5220
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.